Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
23.17
-1.26 (-5.16%)
Dec 3, 2024, 12:20 PM EST - Market open
Enliven Therapeutics Employees
Enliven Therapeutics had 46 employees as of December 31, 2023.
Employees
46
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,852,478
Market Cap
1.13B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 46 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Brookdale Senior Living | 36,000 |
| Pediatrix Medical Group | 5,450 |
| Tilray Brands | 2,650 |
| Embecta | 2,200 |
| Artivion | 1,500 |
| Phreesia | 1,438 |
| Innoviva | 112 |
| Pharvaris | 82 |
ELVN News
- 19 days ago - Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PRNewsWire
- 25 days ago - Enliven Therapeutics to Present at the Jefferies London Healthcare Conference - PRNewsWire
- 2 months ago - Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia - GlobeNewsWire
- 2 months ago - Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML - GlobeNewsWire
- 6 months ago - Enliven Therapeutics to Present at Two Upcoming Investor Conferences - GlobeNewsWire
- 7 months ago - Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update - GlobeNewsWire
- 8 months ago - Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia - GlobeNewsWire
- 8 months ago - Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors - GlobeNewsWire